No Carolina / NY / Florida
Ph: 561.316.3330

Atraverse Medical Receives FDA Clearance for HOTWIRE™ Left Heart Access Device, Oversubscribes Seed Round with $12.5M Invested

Summation

  • Mickelsen, also a cardiac electrophysiology physician at Scripps Hospital in La Jolla, CA, commented, “The FDA clearance of the HOTWIRE underscores our dedication to medical innovation and our commitment to improving the standard of care for procedures requiring transseptal access including endocardial ablation, left atrial appendage closure, and mitral valve repair.
  • John Slump, CEO/President and Co-Founder of Atraverse Medical, remarked, “We are thrilled to have achieved FDA clearance in less than two years since founding the company, and the completion of our seed round positions Atraverse Medical for continued success in transforming the landscape of left-heart access.
  • Atraverse Medical, a San Diego-based medical device company, today announces the FDA clearance of its HOTWIRE™ radiofrequency (RF) guidewire, a novel device that enables zero exchange left-heart access while also acting as a rail for catheter-based therapy systems.

Atraverse Medical, a San Diego-based medical device company, today announces the FDA clearance of its HOTWIRE™ radiofrequency (RF) guidewire, a novel device that enables zero exchange left-heart access while also acting as a rail for catheter-based therapy systems. This milestone achievement marks a significant step towards commercializing the company’s best-in-class left-heart access technology.

The HOTWIRE system, invented by Atraverse Medical Co-Founders Dr. Steven Mickelsen and Eric Sauter, introduces a paradigm shift in left-heart access. Featuring universal sheath compatibility and optimized RF technology, the HOTWIRE aims to improve patient outcomes and streamline procedural workflows. Dr. Mickelsen, also a cardiac electrophysiology physician at Scripps Hospital in La Jolla, CA, commented, “The FDA clearance of the HOTWIRE underscores our dedication to medical innovation and our commitment to improving the standard of care for procedures requiring transseptal access including endocardial ablation, left atrial appendage closure, and mitral valve repair.”

Dr. Devi Nair, Director of Cardiac Electrophysiology and Research at St. Bernard’s Medical Center, along with other key opinion-leading physicians will present their initial experience using the HOTWIRE during the Heart Rhythm Society (HRS) meeting in Boston, MA on May 18, 2024. “I am excited about the HOTWIRE’s ability to drive impactful change in the field of left-heart therapies, allowing physicians to use their preferred transseptal access workflow with the potential for safer, faster procedures,” stated Dr. Nair. Following the recent FDA clearance, Atraverse will conduct demonstrations of the HOTWIRE at the company’s tech suite in the HRS exhibit hall. Prior to HRS, Dr. Mickelsen will introduce the new device during the prestigious Stanford Biodesign New Arrhythmia Technologies Retreat.

Today, Atraverse Medical also announces the oversubscription of its seed round. The company has secured $12.5 million of total seed investment, demonstrating a strong investor belief in the need for continued innovation in the left-heart access arena. This financing includes investment from world-class physicians, reputable venture investors, and successful medtech entrepreneurs and will accelerate the company’s research and development efforts as well as early commercialization initiatives. John Slump, CEO/President and Co-Founder of Atraverse Medical, remarked, “We are thrilled to have achieved FDA clearance in less than two years since founding the company, and the completion of our seed round positions Atraverse Medical for continued success in transforming the landscape of left-heart access.”

Other FDA News of Interest

Indica Labs Receives FDA Clearance for HALO AP Dx Digital Pathology Platform for Use with Hamamatsu Images Acquired with the NanoZoomer® S360MD Slide Scanner

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the...

FDA Grants AI-Powered Notal Vision Home OCT “SCANLY” De Novo Marketing Authorization

“We are very excited to receive FDA authorization to market SCANLY Home OCT as the first-ever patient self-operated, home-use device that gives physicians remote access to high-resolution, cross-sectional retinal images and AI-based analytical biomarkers of their patients eyes between office visits,” said Kester Nahen, PhD, CEO of Notal Vision. “We look forward to supporting our referring physicians in navigating their wet AMD patients’ care.”

RapidAI Secures FDA Clearance for Perfusion Imaging in the Angiography Suite

“We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow™ by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke patients.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy